Citi cuts recommendation for US stocks as recession fears hit, lifts view on China
Citi analysts cut their recommendation for U.S. stocks to "neutral" from "overweight" on Monday after recession fears pummelled the market, arguing that the U.S. economy may no longer outpace the rest of the world in the coming months.
At the same time, they upgraded their view on China to "overweight" from "neutral".
The report was issued after the close of trade on Monday when the Nasdaq lost 4%, its steepest one-day tumble since 2022. The benchmark SP 500 fell 2.7%, its biggest daily drop of the year.
Dirk Willer, Citi's global head of macro, asset allocation and emerging market strategy, said in a note to clients that two recent price signals contributed to the shift in view: the SP 500 breaking below its 200-day moving average and the soft performance of "generals" or market-leading stocks.
"In the big picture, US equity outperformance may well return when the AI narrative takes over again, but in the coming months, we expect US growth momentum to undershoot the (rest of the world)," the note said.
On China, Citi's economists have revised their forecast for Chinese GDP growth to 4.7% this year from 4.5%, partly on a boost from investment in artificial intelligence.
Willer also noted China's tech sector is cheap relative to global peers, even after recent gains.
"China screens well," said Willer. "While tariffs remain a risk ... there is also the possibility of reaching resolution in trade discussions with China, which would be very positive."
In credit, Citi also downgraded U.S. high-yield debt to "neutral" from "overweight."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TECHx
20 minutes ago
- TECHx
AMD EPYC Powers Nokia Cloud Platform for 5G Efficiency
Home » Emerging technologies » Cloud Computing » AMD EPYC Powers Nokia Cloud Platform for 5G Efficiency AMD (NASDAQ: AMD) announced that Nokia has integrated 5th Gen AMD EPYC™ processors into the Nokia Cloud Platform. This move brings enhanced performance and power efficiency to next-generation telecom infrastructure. According to AMD, the processors will help telecom operators manage the growing complexity and scale of 5G networks. Dan McNamara, senior vice president and general manager of AMD's Server Business, stated that customers need solutions offering performance, scalability, and energy efficiency. He added that AMD is working with Nokia to deliver high-performance and efficient networks using 5th Gen AMD EPYC processors. Nokia reported that this extended collaboration highlights its commitment to innovation through diverse chip partnerships in 5G infrastructure. Kal De, senior vice president of Product and Engineering, Cloud and Network Services at Nokia, noted the processors support Nokia's goals of performance and sustainability. The AMD EPYC 9005 Series will power containerized workloads critical to: 5G Core Edge computing Enterprise applications By deploying the processors within its Cloud Platform, Nokia aims to deliver strong performance per watt. This is a key requirement for modern telecom networks that must handle rising data demands while reducing environmental impact. The companies revealed that the partnership will offer telecom customers solutions that meet high-performance needs with better energy use.
Web Release
2 hours ago
- Web Release
Central Pattana & Partners Invest THB 1B in ‘Summer Grand Sale 2025' to Boost Tourism and Thailand's Shopping Appeal
Central Pattana plc, Thailand's leading real estate developer and operator of Central shopping centers nationwide, is teaming up with affiliates under Central Group and key partners across both public and private sectors to launch the Summer Grand Sale 2025—the biggest mid-year sale shopping event of the year. With an investment of THB 1 billion, the campaign offers discounts of up to 80% from over 28,000 brands and 12,000 stores across Central shopping centers. It targets a global audience, including short-haul, long-haul, and high-spending international shoppers. The event will run from 30 May to 13 July 2025 at premier locations including centralwOrld, Central Village Outlet, Central Pattaya, Central Marina Outlet, Central Samui, and Central Phuket. This landmark campaign is backed by Thailand's largest retail alliance, including Central Retail, Central Pattana shopping centers, Central Department Store, Robinson Department Store, Central Online (Central App), Supersports, Central Marketing Group (CMG), Tops Food Hall, Tops, Tops Care, GO Wholesale, Power Buy, OfficeMate, B2S, Robinson Lifestyle, Central Restaurants Group, Centara Hotels and Resorts, GO Hotel, Jubilee Diamond, Evolt Technology, Major Cineplex, SF Cinema, and The 1. It is also supported by the Tourism Authority of Thailand and other strategic partners. Central Pattana continues to collaborate closely with the Tourism Authority of Thailand under the Amazing Thailand Grand Sale campaign to establish Thailand as a premier global shopping destination. This campaign aims to highlight Thailand as a destination rich in food, culture, and shopping experiences. The campaign strategically targets quality tourists, including travelers from Middle East, China, Singapore, Hong Kong, Taiwan, and Malaysia, as well as long-haul visitors from Russia, Europe, the US, and Central Asia. Insights reveal diverse shopper preferences: Chinese tourists often seek Thai fashion and popular eateries; Hong Kong and Singaporean travelers gravitate toward craft goods and Thai desserts; Europeans and Americans favor international fashion brands and premium restaurants, while Middle Eastern and Russian tourists are especially drawn to luxury goods. Central Pattana continues to attract high-spending tourists— 'Quality Shoppers'—as demonstrated by growing e-wallet spending in key tourist malls such as Central Phuket, Central Chiangmai, Central Pattaya, and centralwOrld. This sustained growth reflects the success of its strategic efforts to drive premium tourism. Exclusive Offers for International Visitors: During Summer Grand Sale 2025, international tourists can enjoy exclusive promotions by signing up for The 1 Tourist membership. Members receive a free Tourist Welcome Package with discounts of up to 40%* at participating brands across all Central shopping centers in Thailand. Shoppers who spend THB 6,000* (or THB 5,000* for Klook customers) will receive a complimentary Good Goods Tote Bag valued at THB 690. Offers are available from 30 May to 13 July 2025 at the participating Central locations listed above.
Arabian Post
4 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
